|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Anti-Cancer(Oncology) Agents
|
Idelalisib(CAL-101;GS-1101)
| Catalogue No. : |
C13422 |
| Product Name: |
Idelalisib(CAL-101;GS-1101) |
| Synonym: |
CAL101;GS-1101;GS1101;GS 1101;CAL 101;Idelalisib |
| Chemical Name: |
(S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one;5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone |
| CAS No. : |
870281-82-6 |
| Structure : |
|
| Molecular Formula: |
C22H18FN7O |
| Molecular Weight: |
415.42 |
| Appearance: |
White to off-white solid |
| Solubility: |
DMSO |
| Purity: |
>99% |
| Usage: |
CAL-101 is a potent PI3K p110δ inhibitor with an IC50 of 65 nM. CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis. CAL-101 has 40 to 300-fold selectivity compared to other PI3K isoforms. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
